

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 11, 2025**

**ANEBULO PHARMACEUTICALS, INC**  
**(Exact name of Registrant as Specified in Its Charter)**

**Delaware  
(State or Other Jurisdiction  
of Incorporation)**

**001-40388  
(Commission  
File Number)**

**85-1170950  
(IRS Employer  
Identification No.)**

**Anebulo Pharmaceuticals, Inc.  
1017 Ranch Road 620 South, Suite 107  
Lakeway, TX  
(Address of Principal Executive Offices)**

**78734  
(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (512) 598-0931**

**Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock, \$0.001 par value per share</b>	<b>ANEB</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On April 11, 2025, the Company received a letter from the Staff of The Nasdaq Stock Market LLC (the "Nasdaq") informing the Company, that based on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2025, disclosing that the Company's stockholders had approved the removal of certain voting and transfer restrictions on shares of its common stock issued in its December 2024 private placement, Nasdaq had determined that the Company had regained compliance with Nasdaq Listing Rule 5635(b) and has closed the matter.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 15, 2025

By: /s/ Richard Anthony Cunningham  
Richard Anthony Cunningham  
Chief Executive Officer (*Principal Executive Officer*)

---